Tough Q1 In US For Glenmark, Eyes on Ryaltris Debut, Flovent Rival Filing

Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.

Glenmark readies launches amid challenging US environment • Source: Shutterstock

Glenmark Pharmaceuticals Limited has had a difficult run in the US in the fiscal first quarter though the firm expects things to steady hereon as new launches kick in, including the anticipated debut of Ryaltris (olopatadine hydrochloride/mometasone furoate nasal spray) “anytime now”.

At the earnings call for the fiscal first quarter ended 30 June 2022, Glenmark’s leadership echoed what some peers have...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip